Trial Profile
Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Darunavir; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms RADAR
- 05 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2013 Forty-eight week results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
- 31 Aug 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.